Moderna Dirección

Dirección controles de criterios 3/4

El CEO de Moderna's es Stephane Bancel , nombrado en Oct 2011, tiene una permanencia de 12.5 años. compensación anual total es $17.07M, compuesta por 9.2% salario y 90.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 5.5% de las acciones de la empresa, por valor de €2.09B. La antigüedad media del equipo directivo y de la junta directiva es de 4 años y 9.9 años, respectivamente.

Información clave

Stephane Bancel

Chief Executive Officer (CEO)

US$17.1m

Compensación total

Porcentaje del salario del CEO	9.2%
Permanencia del CEO	12.6yrs
Participación del CEO	5.5%
Permanencia media de la dirección	4.1yrs
Promedio de permanencia en la Junta Directiva	10yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Stephane Bancel en comparación con los beneficios de Moderna?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$6b
Dec 31 2023	US$17m	US$2m	-US$5b
Sep 30 2023	n/a	n/a	-US$3b
Jun 30 2023	n/a	n/a	US$1b
Mar 31 2023	n/a	n/a	US$5b
Dec 31 2022	US$19m	US$1m	US$8b
Sep 30 2022	n/a	n/a	US$12b
Jun 30 2022	n/a	n/a	US$14b
Mar 31 2022	n/a	n/a	US$15b
Dec 31 2021	US$18m	US$990k	US$12b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$3b
Mar 31 2021	n/a	n/a	US$598m
Dec 31 2020	US$13m	US$946k	-US$747m
Sep 30 2020	n/a	n/a	-US$597m
Jun 30 2020	n/a	n/a	-US$488m
Mar 31 2020	n/a	n/a	-US$505m
Dec 31 2019	US$9m	US$921k	-US$514m
Sep 30 2019	n/a	n/a	-US$535m
Jun 30 2019	n/a	n/a	-US$499m
Mar 31 2019	n/a	n/a	-US$459m
Dec 31 2018	US$59m	US$863k	-US$402m
Sep 30 2018	n/a	n/a	-US$299m
Jun 30 2018	n/a	n/a	-US$280m
Mar 31 2018	n/a	n/a	-US$266m
Dec 31 2017	US$7m	US$651k	-US$270m

Compensación vs. Mercado: La compensación total de Stephane($USD17.07M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD5.57M).

Compensación vs. Ingresos: La compensación de Stephane ha sido consistente con los resultados de la empresa en el último año.

CEO

Stephane Bancel (50 yo)

12.6yrs

Permanencia

US$17,068,514

Compensación

Mr. Stephane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel serves as Interim President of Valera LLC. Mr. Bancel serves as a Special Partner at Flagship Pioneering since F...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephane Bancel	CEO & Director	12.6yrs	US$17.07m	5.5% $ 2.4b
Stephen Hoge	President	no data	US$7.34m	0.43% $ 187.0m
James Mock	Chief Financial Officer	1.7yrs	US$4.32m	0.0013% $ 576.1k
Shannon Klinger	Chief Legal Officer & Corporate Secretary	2.9yrs	US$4.31m	0.0024% $ 1.1m
Jerh Collins	Chief Technical Operations & Quality Officer	1.3yrs	sin datos	sin datos
Brad Miller	Chief Information Officer	1.3yrs	sin datos	sin datos
Lavina Talukdar	Senior VP & Head of Investor Relations	5.1yrs	sin datos	sin datos
Colleen Hussey	Senior Director of Corporate Communications	no data	sin datos	sin datos
Tracey Franklin	Chief Human Resources Officer	4.6yrs	sin datos	sin datos
Melanie Ivarsson	Chief Development Officer	4.3yrs	sin datos	sin datos
Dave Johnson	Chief Data & AI Officer	no data	sin datos	sin datos
Charbel Haber	Senior VP & Head of Global Regulatory Science	4.1yrs	sin datos	sin datos

4.1yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0QF se considera experimentado (4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephane Bancel	CEO & Director	13.2yrs	US$17.07m	5.5% $ 2.4b
Noubar Afeyan	Co-Founder	14.3yrs	US$663.52k	0.53% $ 230.8m
Elizabeth Tallett	Independent Director	3.8yrs	US$481.27k	0.00018% $ 78.6k
Robert Langer	Independent Non Executive Director & Member of Scientific Advisory Board	13.4yrs	US$461.27k	3% $ 1.3b
Scott Canute	Member of Technology Advisory Board	10yrs	sin datos	sin datos
Elizabeth Nabel	Independent Director	3.2yrs	US$476.25k	0.00055% $ 240.0k
Fred Regnier	Member of Technology Advisory Board	10yrs	sin datos	sin datos
Francois Nader	Independent Non Executive Director	4.4yrs	US$481.27k	0.0054% $ 2.3m
James Swartz	Member of Technology Advisory Board	10yrs	sin datos	sin datos
Ulrich von Andrian-Werburg	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jack Szostak	Chairman of Scientific Advisory Board	10yrs	sin datos	sin datos
John Aunins	Member of Technology Advisory Board	10yrs	sin datos	sin datos

10.0yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 0QF son experimentados ( 10 años antigüedad media).

Moderna Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Moderna, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently sold €2.2m worth of stock

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Chantal Friebertshäuser Joins Moderna, Inc. as Senior Vice President of Commercial - Europe, Middle East and Canada, Effective January 1, 2023

Recent updates

Moderna Announces Update on Investigational Rsv Vaccine

First quarter 2024 earnings released: US$3.08 loss per share (vs US$0.20 profit in 1Q 2023)

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Insufficient new directors

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

New major risk - Share price stability

Full year 2023 earnings released: US$12.34 loss per share (vs US$21.22 profit in FY 2022)

Moderna, Inc., Annual General Meeting, May 06, 2024

CEO & Director recently sold €2.2m worth of stock

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings released: US$9.53 loss per share (vs US$2.67 profit in 3Q 2022)

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Investor sentiment deteriorates as stock falls 17%

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Investor sentiment improves as stock rises 20%

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$3.62 loss per share (vs US$5.55 profit in 2Q 2022)

Merck and Moderna, Inc. Initiate Phase 3 Study Evaluating V940 (Mrna-4157) in Combination with Keytruda(R) (Pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage Iib-Iv) Melanoma

Moderna, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Moderna Announces Global Regulatory Submissions for its Respiratory Syncytial Virus (RSV) Vaccine, mRNA-1345

Moderna, Inc. Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Growth Index

Moderna, Inc. Completes Submission of A Regulatory Application to the U.S. Food and Drug Administration for Its Updated COVID-19 Vaccine Containing Spike Proteins for the XBB.1.5 Sublineage of SARS-CoV-2

Moderna and Merck Announces mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

First quarter 2023 earnings released: EPS: US$0.20 (vs US$9.10 in 1Q 2022)

Full year 2022 earnings released: EPS: US$21.22 (vs US$30.28 in FY 2021)

Investor sentiment deteriorates as stock falls 15%

Moderna, Inc. Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate

Moderna, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

Moderna, Inc. (NasdaqGS:MRNA) entered into a definitive agreement to acquire OriCiro Genomics, Inc for $85 million.

Investor sentiment deteriorated over the past week

Chantal Friebertshäuser Joins Moderna, Inc. as Senior Vice President of Commercial - Europe, Middle East and Canada, Effective January 1, 2023

Moderna, Inc. and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

Investor sentiment improved over the past week

Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

Moderna, Inc. Announces Executive Changes

Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

Moderna, Inc. Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

Third quarter 2022 earnings released: EPS: US$2.67 (vs US$8.25 in 3Q 2021)

Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222

Investor sentiment improved over the past week

EMA Recommends Authorization of Moderna Vaccine

Moderna, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad